Psychedelic Alpha

Welcome to the Psychedelic News Feed, a podcast from Psychedelic Alpha.

Each episode brings you up to speed with the latest across psychedelic drug development, policy, and access from around the world.

It's presented by me, Josh Hartman, Psychedelic Alpha's founder and editor.

These are intended to be concise summaries as opposed to deep dives.

If you are looking for more nuanced analysis, exclusive interviews, and unrivaled reporting on these topics and much more, head to psychedelicalpha.com.

There have been many efforts to get Ibogaine into human studies in the U.S. that have been sort of delayed.

by issues with opening an investigational new drug application and perhaps even more preclinical work is needed to do so before we get into humans, at least in the US.

So our Psychedelic Alpha Plus subscribers can read much more in our dispatch from that day, which includes coverage of panels featuring FDA staff and

Like, if your mission is you wanna make these drugs available, you wanna make them safe, you wanna get them out of the kind of woo woo underground and available for a population that wouldn't go to psychedelic ceremonies, you need to get them through regulatory approval to do that.

You kind of hit into these constraints and a guy named Josh Hardman who runs a, a site called Psychedelic Alpha, they're like really good analysts of the industry, he just described it as like trying to shoehorn psychedelics into the system that we have.

And yeah, I guess it's like watch this space.

My reporting ended before the big pharma deal.